

Competitor Analysis: WT1-Targeted Immunotherapy

<https://marketpublishers.com/r/C38D52304B7EN.html>

Date: June 2018

Pages: 52

Price: US\$ 354.00 (Single User License)

ID: C38D52304B7EN

Abstracts

Competitor Analysis: WT1-Targeted Immunotherapy

This Competitive Intelligence report analyzes the competitive field of WT1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.

Wilms' tumor 1 (WT1) oncoprotein is a zinc finger transcription factor whose expression in normal adult tissue is rare but is overexpressed in leukemias of multiple lineages and a wide range of solid tumors. WT1 expression is a biomarker and a prognostic indicator. RNA interference knockdown studies of WT1 suggest that it has oncogenic potential and it appears to be expressed in leukemia stem cell populations. A National Institutes of Health–convened panel ranked WT1 as a top cancer target for immunotherapy. WT1 is a nuclear protein, inaccessible to classical antibody therapy, but vaccine approaches are under way to generate WT1-specific cytotoxic T cell (CTL) responses that recognize peptides presented on the cell surface by MHC class I molecules. Engineering autologous T-cells with a WT1-specific T-cell receptor (TCR) is another approach currently pursued.

The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes and recombinant antibodies targeting Wilms Tumor 1 (WT1). In addition, the report lists company- and institution-specific R&D pipelines of WT1-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target/Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

1) WT1-TARGETED IMMUNOTHERAPY

Selective WT1-Targeted Vaccines
WT1-Specific, Multi-Target Vaccines
WT1-Selective Adoptive Cell Therapy
WT1-Specific, Multi-Target Adoptive Cell Therapy
WT1-Targeted Antibodies

2) CORPORATE & INSTITUTIONAL WT1 IMMUNOTHERAPY R&D PIPELINES

I would like to order

Product name: Competitor Analysis: WT1-Targeted Immunotherapy

Product link: <https://marketpublishers.com/r/C38D52304B7EN.html>

Price: US\$ 354.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C38D52304B7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970